Compare AGCO Corporation (AGCO) vs ARK Genomic Revolution ETF (ARKG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AGCO Corporation vs ARK Genomic Revolution ETF — how do they compare? AGCO Corporation trades at $112.96 (market cap $8.24B), while ARK Genomic Revolution ETF trades at $41.07. The key difference: AGCO Corporation pays a 1.05% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, AGCO Corporation nearer its low. Which is the better fit depends on your goals.
| AGCO | ARKG | |
|---|---|---|
Market Cap | $8.24B | — |
Sector | Industrials | Sector/Thematic |
52-Week High | $140.49 | $43.57 |
52-Week Low | $100.14 | $23.09 |
Enterprise Value | $10.41B | — |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGCO trades at $113.75, down 2.35% today, with a neutral technical signal and bullish moving averages. The company shows solid fundamentals with a P/E of 11.41 and net income margin of 7.43%, supported by three consecutive earnings beats. Recent news highlights marketing initiatives and fuel efficiency advancements, while cash flow improved to $249.10M in 2025 from negative levels in prior years.
The outlook remains positive with a consensus price target of $147.50, implying 30% upside, though risks include agricultural sector volatility and debt levels. Earnings momentum and valuation discounts present opportunities, but investor sentiment is balanced with equal buy/hold ratings from analysts.
ARKG trades at $43.57, up 1.54% today, with strong technical momentum as moving averages signal bullish sentiment. The ETF benefits from positive biotech sector trends including FDA friendliness and M&A activity. However, key oscillators show neutral readings with RSI indicators suggesting overbought conditions near the $45 resistance level.
The biotech ETF outlook remains favorable amid sector strength, though elevated RSI levels indicate potential near-term consolidation. Investment opportunity lies in continued sector momentum, while risks include market volatility and selective investor sentiment toward biotech companies as noted by JPMorgan bankers in June 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AGCO Corporation
Agco is a global manufacturer of agricultural equipment. The company has five principal brands: Fendt, Massey Ferguson, Challenger, Valtra, and GSI. Unlike its competitors, Agco's product line extends beyond self-propelled equipment and implements by offering grain handling systems and livestock management solutions. Its products are available through a global dealer network, which includes over 3,200 dealer and distribution locations. Additionally, Agco offers both retail and wholesale financing to customers through its joint venture with Rabobank, a European food and agriculture focused bank.
Read more on AGCO →About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →
